EOLS Q3 2023 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$50M+47.6% YoY

Gross Profit

$35M69.1% margin

Operating Income

-$13M-26.9% margin

Net Income

-$17M-33.8% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+1.4%

Cash Flow

Operating Cash Flow

-$924,000

Free Cash Flow

-$1M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$168M

Total Liabilities

$187M

Stockholders' Equity

-$19M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$34M	+47.6%
Gross Profit	$35M	$20M	+69.5%
Operating Income	-$13M	-$18M	+24.9%
Net Income	-$17M	-$20M	+16.5%

Revenue Segments

Product

$49M99%

Service

$696,0001%